Navigation Links
Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
Date:12/8/2008

illennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is approved in more than 87 countries worldwide.

Important Safety Information

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma. VELCADE also is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension throughout therapy, cardiac and pulmonary disorders, reversible posterior leukoencephalopathy syndrome, gastrointestinal adverse events, thrombocytopenia, neutropenia, tumor lysis syndrome and hepatic events. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Nursing mothers are advised not to breastfeed while receiving VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with no risk factors for decreased left ventricular ejection fraction. There have been reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. There have been reports of Revers
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
2. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
3. Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
4. Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control & Sexual Function in Women
5. New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
6. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
7. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
8. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
11. Portable CT Increases Chance of Stroke Survival and Recovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... According to the new ... (Electric, Battery, Pneumatic), by Product (Drill, Saw, Stapler, ... Application (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global ... Surgical Instruments Market is estimated to be worth ... is expected to grow at a moderate CAGR ...
(Date:11/26/2014)... , Nov. 25, 2014 ... focused on the development of mobile diagnostic ... testing in hospital and pre-hospital settings, today ... (ISO) 13485:2003 certification.  The certification was awarded ... of the world,s leading certification bodies. ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2
... Silence Therapeutics plc (AIM: SLN) ("Silence" or ... patent 7,893,245, titled "Interfering RNA Molecules," by the ... issued patent, which represents a continuation of previously ... RNAi molecules with defined positional modifications including siRNA ...
... Feb. 22, 2011 Covance Inc. (NYSE: CVD ... Annual Morningstar/NYSSA Healthcare Conference on Thursday, February 24, 2011 at ... the presentation at www.covance.com .  In order to register ... early. Covance, with headquarters in Princeton, New Jersey, ...
Cached Medicine Technology:Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 2Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 3Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 4Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference 2
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
(Date:11/27/2014)... 27, 2014 VogueQueen.com is making every ... ladies across the world. As the premier online supplier ... is proud to release a huge selection of sexy ... outfits, it is also providing many beautiful styles in ... gowns at discounted prices. , “VogueQueen.com hopes to ...
(Date:11/27/2014)... This is a professional and ... For an overview analysis, the report introduces Insulin ... structure, industry overview, policy analysis, and news analysis, ... covers information on policy, plans for Insulin Market ... much more. , This report also ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. "Every ... as we enjoy the ugly sweater contest." Last year's ... " It was a sight to see. She glued ... the Christmas balls were faces of the staff with Dr. ... this year, it's simple to get in on the fun. ...
(Date:11/27/2014)... 2014 VeloReality Inc. President Gary ... Life Videos (RLVs) of world-famous velo courses for the company's ... as other popular indoor velo trainers. Two dozen additional Real ... the end of November -- in time for the ... of rides in the VeloReality collection to over sixty. , ...
Breaking Medicine News(10 mins):Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 3
... Support will be held in Las Vegas, NV. LLE - Language ... non-English speaking customers in 150 languages. , ... Washington, D.C. (Vocus) March ... from across the world will gather in Las, Vegas Nevada at the ...
... is now the only over the counter treatment for,chronic and acute ... up the healing process and prevents scar formation. , ... ... is a novel product based on revolutionary technology in the healing ...
... nearly 30 years with Ridgecrest Regional Hospital, Chief Executive Officer David ... with a rich history of healthcare leadership in the state. Suver, ... February 17, has spent his entire healthcare leadership career in California. ... ...
... The popular television show "Extreme Makeover: Home Edition" ... Tucson girl diagnosed with a rare blood disorder who recently ... The program is scheduled to air on the ... (NYBC), whose divisions include Long Island Blood Services, New Jersey ...
... MedQuist Inc., (Nasdaq: MEDQ ) the largest ... announced its financial results for its full year and ... , Net revenues for the year ended December ... for the year ended December 31, 2007. The ...
... can strike younger adults , , WEDNESDAY, March 11 (HealthDay ... for quick diagnosis of a rare but potentially deadly ... death in young people. , The disease is arrhythmogenic ... causes the muscle cells of one of the heart,s ...
Cached Medicine News:Health News:LLE to Deliver Language Interpretation and Translation Solutions at Annual Customer Support Conference 2Health News:LLE to Deliver Language Interpretation and Translation Solutions at Annual Customer Support Conference 3Health News:Wound Be Gone: Quickly Gaining Strong Support from Clinician Experts in the Field of Wound Healing 2Health News:Ridgecrest Regional Hospital Hires New CEO 2Health News:Ridgecrest Regional Hospital Hires New CEO 3Health News:Why Blood and Bone Marrow Donors Are So Important: 'Extreme Makeover: Home Edition' Profiles Blood Drive Honoree Lizzie Bell 2Health News:Why Blood and Bone Marrow Donors Are So Important: 'Extreme Makeover: Home Edition' Profiles Blood Drive Honoree Lizzie Bell 3Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 2Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 3Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 4Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 5Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 6Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 7Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 8Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 9Health News:MedQuist Reports Fourth Quarter and Year End 2008 Results 10Health News:New Test Seems to Spot Deadly Heart Condition 2Health News:New Test Seems to Spot Deadly Heart Condition 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: